옵션 체인은 다양한 행사가격과 만기일에 대한 Lithium Americas의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Lithium Americas에 대한 시장 심리를 평가합니다..

Lithium Americas (NYSE:LAC) 주식, 옵션 체인

Lithium Americas

Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the mid- to late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.

lithium battery

News

Sector ETFs

Global

Markets

ETFs

BATT

iShares S&P Global Clean Energy Index Fund

ICLN

MSFT

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

Market Vectors Rare Earth/Strategic Metals Etf

REMX

TSLA

최근 연구에 따르면 아칸소주가 전기차(EV) 배터리와 기타 첨단 제품에 필수적인 리튬을 상당량 보유하고 있을 가능성이 제기되었다.

아칸소주가 전기차 배터리 수요 증가에 따라 1천 9백만 톤의 리튬을 보유 중으로 예상

Lithium Americas Corp

Lachlan Star Ltd

Lacroix Group

Guidance

UPLD

Upland Software Sees Q2 Sales $50.300M-$56.300M vs $61.17M Est

WIIM

FTRE

Fortrea Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Citizens &amp; Northern Corporation ("C&amp;N") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZNC#NASDAQ">CZNC</a>), headquartered in Wellsboro, Pennsylvania, and Susquehanna Community Financial, Inc. ("SQCF") (OTCPK: SQCF), headquartered in West Milton, Pennsylvania, announced today that both companies' boards of directors have unanimously approved an agreement and plan of merger (the "Agreement") pursuant to which SQCF will merge with and into C&amp;N. C&amp;N is the bank holding company for Citizens &amp; Northern Bank ("C&amp;N Bank"), which operates 28 banking offices and one loan production office in Pennsylvania and New York. As of March 31, 2025, C&amp;N had consolidated assets of $2.6 billion. SQCF is the financial holding company for Susquehanna Community Bank ("Susquehanna"), which operates 7 banking offices in Central Pennsylvania. SQCF had assets of $598 million as of March 31, 2025. In connection with the merger of the holding companies, SQCF's bank subsidiary, Susquehanna, will be merged into C&amp;N Bank. The combined company will have approximately $3.2 billion in assets and will be the premier Pennsylvania community bank in the northern tier, central and southeast Pennsylvania. This strategic combination represents a substantial extension of legacy C&amp;N markets, creating additional scale in central Pennsylvania, while enhancing C&amp;N Bank's capacity to provide exceptional service and solutions to its clients across the Commonwealth. In addition, C&amp;N will further diversify its loan portfolio and funding base, increasing its resiliency and efficiency. The combined entity will successfully align its core values to ensure best-in-class service to the Pennsylvania community. A joint announcement of the transaction was made today by J. Bradley Scovill, President and CEO of C&amp;N, and David S. Runk, Chief Executive Officer of SQCF. Mr. Scovill stated, "This combination continues our strategic efforts to enter attractive markets through acquisition and leverages the strengths of two reputable community banks that share a similar culture and customer-first mindset." He continued, "We believe this is a great fit and we are pleased to welcome Dave and the SQCF team and customers to C&amp;N as we work together to expand our presence in Central Pennsylvania."&nbsp; SQCF shareholders will receive 0.80 shares of C&amp;N common stock for each share of SQCF common stock held, which based on C&amp;N's most recent closing price implies a price per share of $15.58 or $44.3 million in total consideration. Holders of SQCF common stock prior to the consummation of the merger will own approximately 13% of C&amp;N's common stock outstanding immediately following the consummation of the merger. The merger is expected to be approximately ~17% accretive to earnings per share in 2026, while resulting in single-digit tangible book value dilution at close, demonstrating a strong balance of strategic growth and financial discipline. &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

CZNC

Citizens & Northern To Acquire Susquehanna Community Financial In All-Stock Merger Valued At $44.3M, With SQCF Shareholders Receiving 0.80 C&N Shares Per SQCF Share

Earnings

Earnings Beats

Upland Software Q1 Adj. EPS $0.23 Beats $0.17 Estimate, Sales $63.66M Beat $61.17M Estimate

UPXI

Upexi shares are trading higher after the company announced it purchased 326,347 units of Solana to be the largest publicly traded Solana treasury company.

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and lowers the price target from $19 to $14.

Price Target

Analyst Ratings

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $14

ORLA

Orla Mining shares are trading lower after the company reported worse-than-expected Q1 sales results.

Fueling R&amp;D of New Industrial Robots and Asia-Pacific Manufacturing Base Expansion
Shenzhen, China, May 12, 2025 (GLOBE NEWSWIRE) -- Lianhe Sowell International Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) (the "Company"), a provider of machine vision products and solutions applied in a wide range of businesses across industries in China, today announced it received a letter of intent (the "LOI") from a large investment fund in China, Hangzhou Yuhang Economic Development Equity Investment Fund (the "Fund"), for a funding of no more than RMB200 million. The Company plans to apply the investment primarily to support the R&amp;D of its next-generation industrial robots and the construction of the Company's manufacturing base in Hangzhou, Zhejiang province. The LOI is non-binding and the final investment terms will be subject to a definitive agreement between the Company and the Fund.

LHSW

Lianhe Sowell International Group Receives LOI From Hangzhou Yuhang Economic Development Equity Investment Fund For Funding Of No More Than RMB200 Mln

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $36 to $34.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $34

Vicon Industries, a subsidiary of Cemtrex Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) and a leading provider of advanced security and surveillance solutions, today announced that it has officially received the STQC certification from India's Ministry of Electronics and Information Technology (MeitY), marking a major milestone in the company's global expansion strategy.
With this certification, Vicon becomes one of the select few surveillance manufacturers to meet the stringent cybersecurity and quality standards under India's IoT Security Compliance for Surveillance Cameras Scheme (IoTSCS-ER). The designation enables Vicon to market and sell its certified products into India's regulated government, infrastructure, and smart city segments, sectors that are otherwise closed to non-certified providers.

CETX

Cemtrex's Vicon Industries Secures STQC Certification From India's Ministry Of Electronics And Information Technology

Management

WEC Energy Group Appointed Michael Hooper Executive Vice President And Chief Operating Officer

Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction.
What Happened: &nbsp;CNBC&#8217;s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the Commerce Clause of the Constitution and suggested they may not hold up under legal scrutiny. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Price controls are not like tariffs. They are covered by the Commerce Clause of the Constitution. These drug controls most likely will not stand. The drug companies should move for an injunction today, or they are really ill-advised
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1921870793585156494?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This follows President Donald Trump's May 12, 2025, announcement to align U.S. drug prices with lower international rates—a move that triggered a decline in pharmaceutical stocks. Cramer's push for an injunction is a calculated effort to challenge the policy, citing federal overreach as a legal basis.
&#8220;The drug companies should move for an injunction today, or they are really ill-advised,&#8221; wrote Cramer.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/05/45339289/bitcoin-taps-105000-ethereum-steady-dogecoin-falls-as-us-announces-china-trade-deal-analyst-says-btc-in-for-a-price-discovery-uptrend-if-it-secures-a-weekly-close-above-this-lev" target="_blank" rel="noreferrer noopener">Bitcoin Taps $105,000, Ethereum Steady, Dogecoin Falls As US Announces China Trade Deal: Analyst Says BTC In For A &#8216;Price Discovery Uptrend&#8217; If It Secures A Weekly Close Above This Level &#8211; Grayscale B</a>
Why It Matters: Trump&#8217;s <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">announcement</a>, described as the "most consequential executive order" in U.S. history, intends to implement a "Most Favored Nations" policy. This policy requires pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Trump&#8217;s move is expected to slash prescription drug prices by<a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran"> 30% to 80%</a> &#8216;almost immediately.&#8217; However, Cramer&#8217;s argument suggests that this policy may face legal challenges. In another post on Truth Social on Monday, Trump specified that he would lower drug prices by 59%. 
Meanwhile, billionaires Mark Cuban and Bill Ackman have shown support for Trump&#8217;s executive order. Cuban has also <a href="https://www.benzinga.com/markets/equities/25/05/45344525/mark-cuban-slams-charlie-kirk-over-drug-price-debate-says-pbms-not-big-pharma-are-the-real-villains-for-your-companyask-your-pbm-for-a-list-of-claims">pointed out</a> that Pharmacy Benefit Managers (PBMs), not Big Pharma, are the main culprits behind high drug prices due to their opaque pricing practices and market dominance, urging Trump to force transparency.
Notably, the U.S. pays nearly three times more for prescription drugs than other developed nations and Trump's first-term attempt to lower prices was blocked by the courts.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45339966/bitcoin-creator-satoshi-nakamotos-estimated-wealth-crosses-bill-gates-amid-apex-cryptos-sharp-rebound" target="_blank" rel="noreferrer noopener">Bill Gates Left Behind By Satoshi Nakamoto: Bitcoin Creator&#8217;s Wealth Now Eclipses That Of Microsoft Co-Founder Amid Crypto&#8217;s Sharp Rebound</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Economics

General

Jim Cramer Says 'Price Controls Are Not Like Tariffs' — Urges Drugmakers To Challenge Trump's Plan With 'Injunction'

Comstock Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) reported quarterly earnings of $0.15 per share. This is a 66.67 percent increase over earnings of $0.09 per share from the same period last year. The company reported $12.64 million in sales this quarter. This is a 18.81 percent increase over sales of $10.64 million the same period last year.

CHCI

Comstock Holding Co Q1 EPS $0.15 Up From $0.09 YoY, Sales $12.64M Up From $10.64M YoY

Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Hold and lowers the price target from $23 to $21.

PGNY

Canaccord Genuity Maintains Hold on Progyny, Lowers Price Target to $21

Contracts

BOSC

BOS Better Online Solutions Secures Order For Automated End-Of-Line Systems, Combined Value $270K

Landstar System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) will release earnings results for the first quarter, before the opening <a href="https://www.benzinga.com/quote/LSTR/earnings">bell on Tuesday, May 13.</a>
Analysts expect the Jacksonville, Florida-based company to report quarterly earnings at 94 cents per share, down from $1.32 per share in the year-ago period. According to data from Benzinga Pro, Landstar System projects quarterly revenue at $1.13 billion, compared to $1.17 billion a year earlier.
On April 24, Truist Securities analyst Lucas Servera maintained Landstar System with a Hold and lowered the price target from $150 to $135.
With the recent buzz around Landstar System, some investors may be eyeing potential gains from the company's dividends too. Currently, Landstar System offers an annual dividend yield of 1.06% — a quarterly dividend of 36 cents per share. That&#8217;s $1.44 a year.  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $564,879 or around 4,167 shares. For a more modest $100 per month or $1,200 per year, you would need $112,921 or around 833 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.44 in this case). So, $6,000 / $1.44 = 4,167 ($500 per month), and $1,200 / $1.44 = 833 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
LSTR Price Action: Shares of Landstar System fell 0.4% to close at $135.56 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a> </li>
</ul>

Long Ideas

LSTR

How To Earn $500 A Month From Landstar System Stock Ahead Of Q1 Earnings

SECOM Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOMLY#OTC">SOMLY</a>) reported quarterly earnings of $0.11 per share. This is unchanged from the same period last year. The company reported $2.20 billion in sales this quarter. This is a 2.23 percent increase over sales of $2.15 billion the same period last year.

SOMLY

SECOM Co Q4 GAAP EPS $0.11, Same YoY, Sales $2.20B Up From $2.15B YoY

Marriott International shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $226 to $303.

In the preceding three months, 24 analysts have released ratings for Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">15</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $124.79, a high estimate of $155.00, and a low estimate of $82.00. Observing a downward trend, the current average is 11.88% lower than the prior average price target of $141.61. 
<img src="https://www.benzinga.com/files/images/story/2025/1747054876_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Target. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhihan Ma</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$82.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$101.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Belinger</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$82.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$124.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$146.00</td>
<td>$139.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Target. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Target compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Target's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TGT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Target analyst ratings.</a>
<h2>Delving into Target's Background</h2>
Target serves as the nation's seventh-largest retailer, with its strategy predicated on delivering a gratifying in-store shopping experience and a wide product assortment of trendy apparel, home goods, and household essentials at competitive prices. Target's upscale and stylish image began to carry national merit in the 1990s—a decade in which the brand saw its top line grow threefold to almost $30 billion—and has since cemented itself as a leading US retailer.Today, Target operates over 1,900 stores in the United States, generates over $100 billion in sales, and fulfills over 2 billion customer orders annually. The firm's vast footprint is typically concentrated in urban and suburban markets as the firm seeks to attract a more affluent consumer base.
<h3>Target: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Target's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -3.15% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Target's net margin is impressive, surpassing industry averages. With a net margin of 3.57%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Target's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.57%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.9%, the company showcases effective utilization of assets.
Debt Management: Target's debt-to-equity ratio surpasses industry norms, standing at 1.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Target Through The Eyes Of 24 Analysts

Canaccord Genuity analyst George Gianarikas maintains Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) with a Buy and lowers the price target from $4.5 to $3.

LTRX

Canaccord Genuity Maintains Buy on Lantronix, Lowers Price Target to $3

Press Releases

Lithium Americas Increases Mineral Resource and Reserve for Thacker Pass

Lithium Americas Announces Appointment of Luke Colton as EVP and CFO

Commodities

Opinion

Lithium's Role in the Energy Revolution to Regain Momentum in 2025

Gabelli Funds to Host 16th Annual Specialty Chemicals Symposium Thursday, March 20, 2025

NACCO INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Lithium Americas Announces $250 Million Strategic Investment from Orion Resource Partners for Thacker Pass

Lithium Americas Reports 2024 Full Year Results

Lithium Americas Announce FID for Thacker Pass Phase 1 and Closes Strategic Investment from Orion Resource Partners

Comments

Lithium Americas

Lithium Americas (LAC) 옵션

Lithium Americas (NYSE:LAC) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌